{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:08Z","timestamp":1791402308626,"version":"4.3.3"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,15]]},"DOI":"10.1097\/tp.0b013e3182577485","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T13:22:13Z","timestamp":1342704133000},"page":"302-308","source":"Crossref","is-referenced-by-count":36,"title":["Comparison of Posaconazole Versus Weekly Amphotericin B Lipid Complex for the Prevention of Invasive Fungal Infections in Hematopoietic Stem-Cell Transplantation"],"prefix":"10.1097","volume":"94","author":[{"given":"Anne-Marie","family":"Chaftari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray Y.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Kassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall A.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam I.","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11046-009-9188-6","article-title":"Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.","volume":"168","author":"Wirk","year":"2009","journal-title":"Mycopathologia"},{"key":"R2-15-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbmt.2003.09.014","article-title":"A new era of antifungal therapy.","volume":"10","author":"Wingard","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"R3-15-20210129","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","article-title":". Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"R4-15-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2000.02014.x","article-title":"Towards a targeted, risk-based, antifungal strategy in neutropenic patients.","volume":"110","author":"Prentice","year":"2000","journal-title":"Br J Haematol"},{"key":"R5-15-20210129","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00001432-200108000-00004","article-title":"Antifungal prophylaxis in hematopoietic stem cell transplant recipients.","volume":"14","author":"Marr","year":"2001","journal-title":"Curr Opin Infect Dis"},{"key":"R6-15-20210129","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/10428190500205486","article-title":". Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies.","volume":"46","author":"Martino","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R7-15-20210129","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1705143","article-title":"Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).","volume":"36","author":"Ito","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 6","key":"R8-15-20210129","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1086\/429330","article-title":"Treatment of Candida infections with amphotericin B lipid complex.","volume":"40","author":"Ito","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"suppl 6","key":"R9-15-20210129","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1086\/429333","article-title":"Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.","volume":"40","author":"Chandrasekar","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R10-15-20210129","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":". Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R11-15-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":". Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-15-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":". Posaconazole: a broad-spectrum triazole antifungal.","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R13-15-20210129","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cncr.20554","article-title":". Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.","volume":"101","author":"Hachem","year":"2004","journal-title":"Cancer"},{"key":"R14-15-20210129","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":". Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R15-15-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/14787210.4.3.457","article-title":"Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.","volume":"4","author":"Strasfeld","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R16-15-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":". Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-15-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":". Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"R18-15-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":". European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update.","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R19-15-20210129","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/bmt.2009.259","article-title":". Fungal infection prevention after hematopoietic cell transplantation.","volume":"44","author":"Marr","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"R20-15-20210129","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1439-0507.2006.01264.x","article-title":". Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.","volume":"49","author":"Jansen","year":"2006","journal-title":"Mycoses"},{"key":"R21-15-20210129","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":". A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L AmphABLC Collaborative Study Group.","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R22-15-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.11936","article-title":". Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.","volume":"100","author":"Mattiuzzi","year":"2004","journal-title":"Cancer"},{"key":"R23-15-20210129","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.01448-08","article-title":". Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mgkg), weekly dose (7.5 mgkg), or daily dose (1 mgkg) in peripheral stem cell transplant patients.","volume":"53","author":"Gubbins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-15-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":". High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.","volume":"39","author":"El-Cheikh","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R25-15-20210129","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":". High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R27-15-20210129","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":". Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 studySorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R28-15-20210129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1700737","article-title":". Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients.","volume":"19","author":"Jantunen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R29-15-20210129","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":". In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-15-20210129","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"R31-15-20210129","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","article-title":". Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-15-20210129","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":". Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R33-15-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":". Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R34-15-20210129","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":". Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-15-20210129","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1128\/AAC.00889-09","article-title":". Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers.","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-15-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications.","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-15-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.5144\/1658-3876.2010.167","article-title":". Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study.","volume":"3","author":"El Cheikh","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R38-15-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijantimicag.2007.10.001","article-title":". Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.","volume":"31","author":"Cordonnier","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R39-15-20210129","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients.","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R40-15-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R41-15-20210129","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":". Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of CancerInvasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTCMSG) Consensus Group.","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0b013e3182577485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:28:10Z","timestamp":1620977290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201208150-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3182577485","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,15]]}}}